Commodore Capital Lp
- Regulatory AUM
- $2.4B
- Discretionary
- $2.4B
- Clients
- 3
- Avg AUM / client
- $790M
- Accounts
- 3
- Employees
- 12
AUM over time
Reported AUM from Form ADV filings, plotted by filing date · as of Mar 31, 2026
Investments (13F portfolio — 36 positions, $1,728,452,370)
13F period Mar 31, 2026| # | Issuer | Class | Value | Shares | % of 13F | % of AUM |
|---|---|---|---|---|---|---|
| 1 | Relay Therapeutics Inc | COM | $169,150,000 | 17,000,000 | 9.79% | 7.14% |
| 2 | Alkermes Plc | SHS | $148,512,000 | 4,200,000 | 8.59% | 6.27% |
| 3 | Enliven Therapeutics Inc | COM | $128,380,000 | 3,275,000 | 7.43% | 5.42% |
| 4 | Cogent Biosciences Inc | COM | $111,159,389 | 2,888,007 | 6.43% | 4.69% |
| 5 | Spyre Therapeutics Inc | COM NEW | $96,460,447 | 1,912,380 | 5.58% | 4.07% |
| 6 | Tyra Biosciences Inc | COM | $94,792,500 | 2,475,000 | 5.48% | 4.0% |
| 7 | Celldex Therapeutics Inc New | COM NEW | $85,536,660 | 2,696,616 | 4.95% | 3.61% |
| 8 | Nuvalent Inc | COM | $85,402,320 | 833,600 | 4.94% | 3.6% |
| 9 | Amylyx Pharmaceuticals Inc | COM | $78,535,000 | 5,650,000 | 4.54% | 3.31% |
| 10 | Kymera Therapeutics Inc | COM | $62,467,500 | 750,000 | 3.61% | 2.64% |
| 11 | Alto Neuroscience Inc | COM SHS | $61,217,446 | 2,723,196 | 3.54% | 2.58% |
| 12 | Pharvaris N V | COM | $54,210,903 | 1,918,970 | 3.14% | 2.29% |
| 13 | Erasca Inc | COM | $51,371,500 | 3,175,000 | 2.97% | 2.17% |
| 14 | Damora Therapeutics Inc | COM NEW | $50,220,100 | 1,939,000 | 2.91% | 2.12% |
| 15 | Xenon Pharmaceuticals Inc | COM | $47,973,750 | 825,000 | 2.78% | 2.02% |
| 16 | Definium Therapeutics Inc | COM SHS | $37,800,000 | 2,000,000 | 2.19% | 1.6% |
| 17 | Lb Pharmaceuticals Inc | COM SHS | $36,990,000 | 1,500,000 | 2.14% | 1.56% |
| 18 | Eyepoint Inc | COM NEW | $36,414,250 | 2,825,000 | 2.11% | 1.54% |
| 19 | Nurix Therapeutics Inc | COM | $35,262,500 | 2,275,000 | 2.04% | 1.49% |
| 20 | Corvus Pharmaceuticals Inc | COM | $33,045,293 | 2,258,735 | 1.91% | 1.39% |
| 21 | Assembly Biosciences Inc | COM NEW | $27,750,000 | 1,000,000 | 1.61% | 1.17% |
| 22 | Perspective Therapeutics Inc | COM NEW | $26,424,381 | 6,336,782 | 1.53% | 1.12% |
| 23 | Soleno Therapeutics Inc | COM | $21,843,423 | 652,432 | 1.26% | 0.92% |
| 24 | Ocular Therapeutix Inc | COM | $21,810,250 | 2,575,000 | 1.26% | 0.92% |
| 25 | Century Therapeutics Inc | COM | $19,652,174 | 8,695,652 | 1.14% | 0.83% |
Top 25 of 36 positions from the manager's latest Form 13F · source filing (EDGAR) ↗. 13F covers long US-listed positions only. "% of AUM" is share of the firm's total regulatory AUM (Form ADV Item 5.F).
Who they serve
| Client type | Clients | AUM | % of AUM |
|---|---|---|---|
| Pooled investment vehicles (non-investment companies) | 3 | $2.4B | 100.0% |
Private funds (1)
Reported in Form ADV Section 7.B.(1), filing of Mar 2024 · $1.4B combined gross assets
| Fund | Type | Domicile | Gross assets | Owners |
|---|---|---|---|---|
| Commodore Capital Master Lp master | Hedge Fund | Cayman Islands | $1.4B | 136 |
People (4)
| Name | Role / title | Credentials | With firm since | Ownership |
|---|---|---|---|---|
| Atkinson, Robert Egen, Turrell | Managing Partner | Jun 2019 (7y) | ≈ 18.75% – 50% via Commodore Capital Holdings Lp | |
| Kramarz, Michael, Jonathan | Managing Partner | Jun 2019 (7y) | ≈ 18.75% – 50% via Commodore Capital Holdings Lp | |
| Bapat, Ameya, Vikas | Chief Compliance Officer, Chief Operating Officer, General Counsel | Mar 2022 (4y) | Less than 5% | |
| Pandya, Anand, Bharat | Chief Financial Officer | Feb 2023 (4y) | Less than 5% |
Entity owners (Schedule A/B)
| Entity | Title / status | Since | Sch. | Ownership |
|---|---|---|---|---|
| Commodore Capital Holdings Lp | Limited Partner | Jun 2019 | A | 75% or more |
| Commodore Capital Gp Llc | General Partner | Jun 2019 | A | Less than 5% |
Undisclosed: 0% – 25% of the firm is not attributable from the filed Schedule A bands.
Estimated effective ownership (look-through of filed bands):
- Atkinson, Robert Egen, Turrell: 25% – 50% of Commodore Capital Holdings Lp × 75% – 100% direct ≈ 18.75% – 50% of the firm
- Kramarz, Michael, Jonathan: 25% – 50% of Commodore Capital Holdings Lp × 75% – 100% direct ≈ 18.75% – 50% of the firm
Roster from the IAPD representatives feed; ownership and acquisition dates from Form ADV Schedule A/B. "Since" is the earliest filed registration or acquisition date.
Private funds (1, $1.4B gross assets)
| Fund | Type | Gross assets | Min. investment | Owners |
|---|---|---|---|---|
| Commodore Capital Master Lp | Hedge Fund | $1.4B | $5.0M | 136 |
From Form ADV Section 7.B private fund reporting.
Documents (1 archived)
| Form | Period | Size | |
|---|---|---|---|
| Form ADV (full filing) | 03/31/2026 | 1.22 MB | View · PDF · Source ↗ |
Archived copies of the firm's regulatory filings, versioned by content hash.
Disciplinary disclosures
No disciplinary events reported on the firm's latest Form ADV filing.
How they charge
- • Percentage of assets under management
- • Performance-based fees
Services
- • Portfolio management for pooled investment vehicles
Custody
Firm reports having custody of client funds or securities (Item 9.A).
No custodian data reported or mined yet.
Source
All data on this page comes from this firm's Form ADV filings, reproduced without modification. Latest filing: Mar 31, 2026.
View current Form ADV (SEC/IAPD) ↗